# BP-205 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bp-205

> The PDUFA target action date for BP-205, sponsored by Harmony Biosciences Holdings, Inc. (HRMY), is 2028. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: year only, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the BP-205 PDUFA date?

The PDUFA target action date for BP-205, sponsored by Harmony Biosciences Holdings, Inc. (HRMY), is 2028. Status: scheduled. Press release filed with the SEC (EX-99): "TLD expected in 2027; Anticipated PDUFA in 2028" Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/bp-205)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-122377, https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d2.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/bp-205#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | BP-205 |
| Codes | BP-205 |
| Sponsor | Harmony Biosciences Holdings, Inc. (HRMY) https://sec-api.dev/companies/hrmy/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### 2026: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2026-05-07, last confirmed 2026-05-07.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; plans to submit an NDA for Pitolisant GR; plans to submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an NDA for Pitolisant GR; plans to submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d2.htm

### Jul 2026: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122390): "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and initiated a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm

### Q3 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-05-07, last confirmed 2026-08-04.
- SEC Form 10-Q (accession 0001104659-26-090090): "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and are preparing to initiate a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in early 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "Plan to initiate Phase 1b study in sleep-deprived healthy volunteers in 2H 2026" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-05-07, last confirmed 2026-08-04.
- SEC Form 10-Q (accession 0001104659-26-090090): "Topline data from the Phase 1 multiple ascending dose study is expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-056720): "We filed an investigational medicinal product dossier ("IMPD") with the EMA and began first-in-human studies in the fourth quarter of 2025 with topline data from the single ascending dose part of the study anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1802665/000110465926056720/hrmy-20260331x10q.htm

### early 2027: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-08-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "BP-205 IND Open in US; Initiating Phase 1b Study in Sleep-Deprived Healthy Volunteers in Q3; Data Expected Early 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Next steps in BP-205 development o Multiple ascending dose (MAD) data in healthy volunteers expected in Q4 o US IND open; initiate Phase 1b study in sleep-deprived healthy volunteers in Q3; data expected in early 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-122390): "In addition, we plan to initiate Phase 2 trials for BP-205 in mid-2027 to evaluate multiple CNS indications." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In addition, we plan to initiate Phase 2 trials for BP-205 in mid-2027 to evaluate multiple CNS indications." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "Harmony remains on track to report Phase 1b data in sleep-deprived healthy volunteers in the first quarter of 2027, followed by the initiation of Phase 2 studies across multiple CNS indications by mid-2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "o Phase 1b study in sleep-deprived healthy volunteers initiated in Q3 in the US; data expected in Q1 2027 o Expect to initiate Phase 2 studies to evaluate multiple CNS indications by mid-2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2026-05-07, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001104659-26-122390): "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and initiated a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926122390/hrmy-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-090090): "In July 2026, we submitted an IND for BP-205 to the FDA, which is now open, and are preparing to initiate a Phase 1b study in sleep-deprived healthy volunteers in the third quarter of 2026, with topline data expected in early 2027." https://www.sec.gov/Archives/edgar/data/1802665/000110465926090090/hrmy-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "Topline data anticipated 1H 2027" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "Topline data anticipated in 1H 2027 and potential PDUFA date in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "o Topline data expected in 2027; anticipated PDUFA date in 2028 o Enhanced formulation with optimized PK profile, enteric coating and higher dose to drive greater efficacy o Differentiated labeling: fatigue in narcolepsy and sleep inertia in IH" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm

### 2028: PDUFA date

- Status: scheduled. Date confidence: year.
- First seen 2026-05-07, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "TLD expected in 2027; Anticipated PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "TLD expected in mid-2027; Anticipated PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-122377): "TLD expected mid-2027; Anticipated PDUFA dates in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926122377/hrmy-ex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "TLD expected in 2027; Anticipated PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-090086): "TLD expected in mid-2027; Anticipated PDUFA in 2028" https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804xex99d2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-056786): "o Topline data expected in 2027; anticipated PDUFA date in 2028 o Enhanced formulation with optimized PK profile, enteric coating and higher dose to drive greater efficacy o Differentiated labeling: fatigue in narcolepsy and sleep inertia in IH" https://www.sec.gov/Archives/edgar/data/1802665/000110465926056786/hrmy-20260507xex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bp-205.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BP-205 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bp-205

```bibtex
@misc{secapidev_pdufa_bp_205_20261116,
  title        = {BP-205 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bp-205}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bp_205_20261116","title":"BP-205 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bp-205","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
